Signum Dermalogix licenses SIG990 to Dermata Therapeutics for rosacea

25 March 2015

Dermatology biotech company Signum Dermalogix has entered into an agreement with Dermata Therapeutics to develop a tropical product to treat rosacea.

SIG990 is a novel, first-in-class anti-inflammatory compound with the potential to reduce erythema and decrease the papules and pustules associated with the disease. The Investigational New Drug application for SIG990 has been cleared by the US Food and Drug Administration and the compound is ready to be evaluated in subjects.

Dermata has obtained an exclusive worldwide license to SIG990 and is responsible for the clinical development of the product, while Dermalogix will receive milestone payments and royalties.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK